Clinical implications of HIV-1 drug resistance in the neurological compartment

Research output: Contribution to journalArticlepeer-review

Abstract

The tropism of human immunodeficiency virus type 1 (HIV-1) for the central nervous system (CNS) develops early during the course of the infection. Potent antiretroviral therapy has been demonstrated to be effective in controlling the replication of HIV-1 in cerebrospinal fluid (CSF), even though a variable response in this compartment compared with that in plasma has been observed. Different concentrations of antiretroviral drugs are found in CSF and the use of antiretroviral drugs penetrating across the blood-brain barrier is considered to be required for controlling CNS infection in advanced patients, particularly in those with neurological disorders. The compartmentalization of HIV-1 infection in the CNS may affect the treatment response, which may cause a different evolution of viral drug resistance in the 2 compartments. Although HIV-1 resistance testing in CSF is not recommended for the routine management of patients with virological failure, treatment decisions in patients with neurological disorders may require knowledge of the resistance profile of the virus in the CSF.

Original languageEnglish
Pages (from-to)41-44
Number of pages4
JournalScandinavian Journal of Infectious Diseases
Volume35
Issue numberSUPPL. 106
DOIs
Publication statusPublished - Dec 2003

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Clinical implications of HIV-1 drug resistance in the neurological compartment'. Together they form a unique fingerprint.

Cite this